Transcriptomic signature of response to vedolizumab in patients with moderate-to-severe ulcerative colitis: Results from an international, multicentre, retrospective cohort study

被引：0
|
作者：
Linggi, B. [1 ]
Salas, A. [2 ,3 ]
Veny, M. [2 ,3 ]
Borowski, K. [4 ]
Silverberg, M. S. [4 ,5 ]
Milgrom, R. [4 ]
Stempak, J. [4 ]
Boland, B. [6 ]
Eckmann, L. [6 ]
Smith, M. I. [1 ]
Parker, C. E. [1 ]
Jairath, V. [1 ,7 ,8 ]
Teft, W. [1 ]
Vande Casteele, N. [1 ,6 ]
机构：
[1] Aliment Inc, Med Resesarch & Dev, London, ON, Canada
[2] Fundacio Recerca Clin Barcelona FRCB IDIBAPS Hosp, Inflammatory Bowel Dis Unit, Barcelona, Spain
[3] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inflammatory Bowel Dis Unit, Barcelona, Spain
[4] Sinai Hlth Syst, Zane Cohen Ctr Digest Dis, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
[5] Univ Toronto, Div Gastroenterol, Mt Sinai Hosp, Toronto, ON, Canada
[6] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[7] Western Univ, Dept Epidemiol & Biostat, London, ON, Canada
[8] Western Univ, Dept Med, London, ON, Canada
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
OP40
引用
收藏
页码：I71 / I71
页数：1
相关论文
共 50 条
  • [41] Histological Remission Leads to Less Endoscopic Flare-up in Moderate-to-Severe, Biologics Experienced Ulcerative Colitis Patients: A Comprehensive Retrospective Cohort Study
    Wei, Z. H.
    Le, P. H.
    Chiu, H. Y.
    Yeh, P. J.
    Chiu, C. T.
    Chiu, C. H.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1119 - I1121
  • [42] The baseline features of patients with newly diagnosed moderate-to-severe ulcerative colitis in Korea: A population-based cohort study (the MOSAIK cohort)
    Oh, S. J.
    Moon, J. R.
    Lee, C. K.
    Park, Y. M.
    Hong, S. N.
    Im, J. P.
    Ye, B. D.
    Cha, J. M.
    Jung, S. -A.
    Lee, K. -M.
    Park, D. I.
    Jeen, Y. T.
    Park, Y. S.
    Cheon, J. H.
    Kim, H. -S.
    Kim, Y.
    Kim, H. J.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S270 - S270
  • [43] A metabolomics-driven model for early remission prediction following vedolizumab treatment in patients with moderate-to-severe active ulcerative colitis
    Jiang, Leilei
    Liu, Xiaoming
    Su, Yue
    Chen, Yujie
    Yang, Shaozhi
    Ke, Xiquan
    Yao, Kunhou
    Guo, Zhiguo
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 128
  • [44] Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study
    Chen, Baili
    Zhong, Jie
    Li, Xiuling
    Pan, Feng
    Ding, Yijuan
    Zhang, Yan
    Chen, Hong
    Liu, Fei
    Zhang, Zhenyu
    Zhang, Ling
    Drozda, Rafal
    Oliinyk, Oleksandr
    Goh, Aik Han
    Chen, Xiang
    Sun, Xiang
    Rubin, David T.
    Sandborn, William J.
    Chen, Minhu
    GASTROENTEROLOGY, 2022, 163 (06) : 1555 - 1568
  • [45] Efficacy and Safety of Vedolizumab Combined with Upadacitinib in Moderate-to-Severe Ulcerative Colitis: A Multicenter, Prospective, Randomized Controlled Trial
    Wu, H.
    Su, T.
    Wu, L.
    Zhi, M.
    Yao, J.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i195 - i197
  • [46] Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study
    Sands, Bruce E.
    Sandborn, William J.
    Feagan, Brian G.
    Lichtenstein, Gary R.
    Zhang, Hongyan
    Strauss, Richard
    Szapary, Philippe
    Johanns, Jewel
    Panes, Julian
    Vermeire, Severine
    O'Brien, Christopher D.
    Yang, Zijiang
    Bertelsen, Kirk
    Marano, Colleen
    JOURNAL OF CROHNS & COLITIS, 2018, 12 (10): : 1158 - 1169
  • [47] Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study
    Sandborn, William J.
    Danese, Silvio
    Leszczyszyn, Jaroslaw
    Romatowski, Jacek
    Altintas, Engin
    Peeva, Elena
    Hassan-Zahraee, Mina
    Vincent, Michael S.
    Reddy, Padmalatha S.
    Banfield, Christopher
    Salganik, Mikhail
    Banerjee, Anindita
    Gale, Jeremy D.
    Hung, Kenneth E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2023, 21 (10) : 2616 - 2628
  • [48] Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study
    Meyer, Antoine
    Fumery, Mathurin
    Peyrin-Biroulet, Laurent
    Filippi, Jerome
    Altwegg, Romain
    Bouhnik, Yoram
    Serrero, Melanie
    Laharie, David
    Roblin, Xavier
    Nachury, Maria
    Abitbol, Vered
    Cadiot, Guillaume
    Nancey, Stephane
    Allez, Matthieu
    Gilletta, Cyrielle
    Vuitton, Lucine
    Savoye, Guillaume
    Nahon, Stephane
    Bourrier, Anne
    Buisson, Anthony
    Bouguen, Guillaume
    Bourreille, Arnaud
    Viennot, Stephanie
    Carbonnel, Franck
    Amiot, Aurelien
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2022, 57 (12) : 1454 - 1462
  • [49] Comment on: Effectiveness of Early Thiopurine Use in Korean Patients With Moderate-to-severe Ulcerative Colitis A Prospective Multicenter Cohort (MOSAIK) Study
    Mourad, Fadi H.
    Kariyawasam, Viraj C.
    Leong, Rupert W.
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2025, 59 (02) : 196 - 196
  • [50] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
12345